Breakthrough in Nuclear Medicine as Novartis' Pluvicto Sales Soar to $1.39 Billion in 2024
In a remarkable development within the pharmaceutical sector, Novartis has announced that its nuclear medicine product, Pluvicto (177Lu-PSMA-617), achieved $1.39 billion in sales for the year 2024, marking a 42% increase compared to the previous year. This milestone establishes Pluvicto as the first blockbuster drug in the nuclear medicine field.
Since its approval in the United States in March 2022, Pluvicto has demonstrated impressive growth. In its first year, the drug generated $271 million, which skyrocketed to $980 million in 2023, representing a staggering 261% year-over-year increase. Cumulatively, Pluvicto has contributed $2.643 billion to Novartis’ revenue, with four additional indications currently under investigation, including a Phase III trial for metastatic hormone-sensitive prostate cancer expected to conclude in 2025.
Nuclear medicine is being hailed as a crucial aspect of precision diagnostics and treatment, with experts likening its impact to that of a "missile" in the hands of healthcare providers. According to Dr. Wang Tie, Chief Physician of Nuclear Medicine at Beijing Chaoyang Hospital, nuclear medicine offers unique advantages over traditional cancer therapies, including non-invasive precision diagnostics and integrated therapeutic capabilities. This allows for personalized treatment based on imaging and targeted delivery of radioactive agents to tumors.
The demand for both diagnostic and therapeutic nuclear medicines has surged in recent years, revealing a significant unmet need in cancer treatment. Major pharmaceutical companies are keenly aware of the potential of this market. Besides Novartis, industry giants such as Bayer, Eli Lilly, AstraZeneca, Bristol Myers Squibb, Merck, and Johnson & Johnson are actively investing in nuclear medicine through acquisitions and partnerships. Notably, Bristol Myers Squibb made headlines in December 2023 with its $4.1 billion acquisition of RayzeBio, gaining access to a differentiated platform for alpha-emitting radiopharmaceuticals.
In the domestic Chinese market, competition in nuclear medicine is intensifying. Nearly 20 companies, including Hengrui Medicine, Yuan Da Medicine, and Xiantong Medicine, are rapidly advancing their nuclear medicine portfolios. To date, 24 radioactive drugs have been approved for use, addressing various conditions including prostate cancer, coronary heart disease, neuroendocrine tumors, and Alzheimer's disease.
Innovative domestic products are also emerging, with over 100 nuclear medicine candidates in clinical stages. The most advanced is 99mTc-3PRGD2, developed by Radiopharmaceuticals, which is the first domestically produced innovative nuclear medicine for tumor imaging. This drug has completed Phase III trials and is in the process of seeking market approval. Additionally, Hengrui's 177Lu-labelled octreotate injection is also in Phase III trials, targeting neuroendocrine tumors.
With the nuclear medicine sector rapidly evolving, the future looks promising as companies strive to meet the growing demand for effective cancer diagnostics and treatments.
2026-11-18
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
ContextLogic Acquires gChem for $850 Million in Major Specialty Chemicals Deal
-
$25 Billion Paint Giant Born: AkzoNobel and Axalta Shareholders Approve Merger by Landslide
-
Evonik Evaluates Acquisition of Ashland
-
Evonik Reports Strong Q2 Results as Supply Chain Disruptions Boost Chemical Margins
-
Ineos Exits Sinopec Tianjin Joint Venture, Pays $120 Million "Breakup Fee"
-
Lenzing Group, a European fiber giant with over a century of history, is being forced to close two plants and cut 2,000 jobs globally
-
RMB 30 Billion Olefins Project Issues Second EIA Public Notice; Fuhai Removes Five Units
-
BASF CEO Pushes Evonik Takeover, Pledges Job Protections Until 2032
-
Sika Reports CHF 8.71 Billion Nine-Month Sales, Maintains 2026 Guidance
-
Europe’s Chemical Industry Sounds the “Shutdown Alarm”: It’s Not Just a Few Plants at Risk—The Entire Industrial Chain Is Shaking
Recommend Reading
-
South Korea’s June Petrochemical Export Value Rises 18.8%, While Export Volume Falls 14.6%
-
BASF Approves €1 Billion Share Buyback Program as Chemical Giant Prioritizes Capital Discipline
-
Covestro CEO: The EU Must Decide Which Industries to Protect, or Energy-Intensive Sectors Will Move Out
-
Profit Soars While Sales Dip: Syngenta Group Defies Headwinds with 28% EBITDA Surge in Q3 2025
-
INEOS Warns Chinese Chemical “Dumping” Is Hitting Europe’s Industry
-
gust 24, 2026 View on Isooctanol Market Trends: Strong Volatility
-
Methanol Trend Analysis on November 16, 2026: Strong Consolidation
-
rket Outlook for Isooctanol on August 25, 2026: Volatile Adjustment
-
November 17, 2026 Melamine Trend Analysis in China: Fluctuation
-
Nature’s Blueprint, Science’s Edge: Corteva Unveils Twin Breakthroughs to Tackle the $70 Billion Insect Threat